Valeant Pharmaceuticals built a business model of acquiring smaller drug companies, gutting their R&D departments, and dramatically raising prices on existing drugs (many of which were under patent or life-saving), which created short-term earnings growth but was fundamentally a win-lose model that eventually collapsed.
causalpending
Speaker
Monish PabraiEvidence Quote
“Valiant would acquire smaller drug companies it would gut their R&D departments basically almost wipe them out and they would look at the portfolio of the all drugs that the company was selling and they would increase the hell out of the prices on those drugs”
Created: 8/11/2026, 7:06:50 AM
Your notes
Loading notes...